0000899243-21-009554.txt : 20210303
0000899243-21-009554.hdr.sgml : 20210303
20210303194636
ACCESSION NUMBER: 0000899243-21-009554
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210301
FILED AS OF DATE: 20210303
DATE AS OF CHANGE: 20210303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON DAVID LEE
CENTRAL INDEX KEY: 0001733883
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 21711754
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS
STREET 2: 171 OYSTER POINT BLVD, STE. 300
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001733883
JOHNSON DAVID LEE
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Commercial Officer
Common Stock
2021-02-28
5
A
0
E
375
36.21
A
27407
D
Stock Option (Right to Buy)
44.48
2021-03-01
4
A
0
38739
0.00
A
2031-02-28
Common Stock
38739
38739
D
Restricted Stock Units
2021-03-01
4
A
0
22102
0.00
A
Common Stock
22102
22102
D
Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
/s/ Tricia Suvari, Attorney-in-Fact
2021-03-03